<unk> , sold under the brand name Crysvita, is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.<unk>  was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018. The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Burosumab
Olaratumab
Alirocumab
Emapalumab
Sarilumab
Evolocumab
Lanadelumab
Dupilumab